Overview

A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study seeks to define the tolerability and safety associated with the administration of Dronabinol in the treatment of adults with nausea, vomiting and appetite loss in patients with primary gliomas who are undergoing chemotherapy treatment. The study will also describe the effect of Dronabinol on the quality of life in terms of nausea, vomiting and anorexia in this patient group.
Phase:
Phase 1
Details
Lead Sponsor:
Duke University
Collaborator:
Solvay Pharmaceuticals
Treatments:
Dronabinol